Hørsholm – 2. september 2013 – De europæiske lægemiddelmyndigheder har i dag givet Genzyme, a Sanofi company, tilladelse til at markedsføre Aubagio® (teriflunomid) 14 mg, en daglig tabletbehandling godkendt til voksne patienter med Recidiverende-Remitterende Multipel Sclerose (RRMS, attakvis sclerose).
Genzyme Corporation (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc. today announced study results showing that patients with early relapsing-remitting multiple sclerosis (RRMS) taking once-yearly cycles of alemtuzumab reduced their risk of relapse by 74 percent and the risk of sustained accumulation of disability by 71 percent compared to patients treated with the active comparator Rebif® (high-dose interferon beta-1a). Importantly, the mean disability of patients on alemtuzumab improved from baseline, whereas the mean disability of those on Rebif worsened. The treatment benefits of alemtuzumab were sustained for at least three years, even though the majority of alemtuzumab-treated patients were last dosed two years earlier. These results come from the final three-year analysis of a Phase 2 clinical study (CAMMS223) reported in the Oct. 23 issue of the New England Journal of Medicine. The study involved 334 patients who had not previously been treated for their disease.
Når MS-patienter behandles med Betaferon straks efter sygdomsdebut (første attak) reduceres risikoen for at få endnu et attak og dermed klinisk definitiv MS med 37 procent. Dette viser nyligt fremlagte data for 5 års opfølgning på patienter.